Atomoxetine

Atomoxetine is a non-stimulant medication for ADHD, classed as a selective norepinephrine reuptake inhibitor. ^[1] It was the first non-stimulant drug approved specifically for ADHD, offering an alternative for people who cannot tolerate stimulants, do not respond to them, or where a non-controlled medicine is preferred.

Unlike a stimulant, its therapeutic effect builds gradually over several weeks rather than acting within hours. ^[3] Beyond ADHD it has been studied for related conditions, and comparative reviews consistently show it improves core ADHD symptoms more than placebo in both children and adults, while being modestly less effective on average than stimulant medications. ^[1][2]

Atomoxetine was developed by Eli Lilly and Company and approved by the US Food and Drug Administration in 2002. ^[3] A key practical distinction from stimulants is its legal status: because it has no appreciable misuse or dependence potential, it is not a scheduled controlled substance, which simplifies prescribing and refills. ^[4] Generic versions became available after the patent expired.

A large network meta-analysis of ADHD medications found atomoxetine clearly outperformed placebo on clinician-rated symptoms, though stimulants such as methylphenidate and the amphetamines generally showed larger effects. ^[1] A separate meta-analysis focused on non-stimulants in adults reached the same conclusion, ranking atomoxetine among the effective non-stimulant options. ^[2]

Common side effects include reduced appetite, nausea, stomach upset, fatigue, and small increases in heart rate and blood pressure. ^[3] Regulators require a boxed warning about a small increased risk of suicidal thoughts in children and adolescents, and rare liver injury has been reported. Its clearance depends on the liver enzyme CYP2D6, so people who metabolize it slowly may have stronger effects and more side effects. It is a prescription-only oral medicine taken as capsules.

Atomoxetine is non-addictive and can be stopped without the rebound or withdrawal you get from stimulants, which is a big part of its appeal, but it is a prescription medication with a real side-effect profile. Common complaints are nausea, reduced appetite, dry mouth, dizziness, fatigue, and sleep changes; in adults, urinary hesitancy and erectile dysfunction can show up, and it tends to nudge heart rate and blood pressure up modestly. It carries a boxed warning for increased suicidal thinking in children and adolescents, so mood should be watched early on, and there are rare reports of liver injury. It is processed by CYP2D6, so strong inhibitors of that enzyme (fluoxetine, paroxetine, bupropion) and poor-metabolizer genetics raise blood levels considerably; it should not be combined with MAO inhibitors. Use caution with existing heart or blood-pressure conditions.

The atomoxetine (Strattera) label contraindicates use with monoamine oxidase inhibitors and within 14 days of stopping one, because of the risk of serious, sometimes fatal, noradrenergic reactions resembling serotonin syndrome. Atomoxetine is metabolized primarily by CYP2D6, so strong CYP2D6 inhibitors such as paroxetine, fluoxetine, and quinidine substantially raise its plasma concentrations and may require dose adjustment; CYP2D6 poor metabolizers show similarly elevated exposure. The label also warns about additive cardiovascular effects with pressor agents and other sympathomimetics, including potential blood-pressure and heart-rate increases, and about additive QT prolongation with drugs that prolong the QT interval. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Atomoxetine was first synthesized by Eli Lilly in the 1980s and was originally investigated, under the name tomoxetine, as a candidate antidepressant; it did not prove competitive for depression and was set aside. Researchers later recognized that its selective enhancement of noradrenergic signaling was well suited to attention deficit hyperactivity disorder, and it was redeveloped for that purpose. In November 2002 the U.S. Food and Drug Administration approved it under the brand name Strattera, making it the first non-stimulant medication approved for ADHD and the first drug of any kind approved in the United States for ADHD in adults. Because it is not a controlled substance, it filled a distinct niche among ADHD treatments from the outset.

Atomoxetine is well regarded as a dependable, non-stimulant option, valued especially by clinicians and patients who want steady, around-the-clock symptom coverage without the peaks, troughs, or abuse potential of stimulants. Large network meta-analyses consistently place it among the effective ADHD pharmacotherapies, even if its average effect size sits somewhat below that of the stimulants. It is frequently chosen for people with co-occurring anxiety or tic disorders, or where a controlled substance is undesirable. Its main practical caveat, widely acknowledged, is that benefit builds gradually over several weeks rather than appearing on the first dose.